Fifty patients with acute promyelocytic leukemia (APL) have been treated with all-trans retinoic acid (RA). In vitro induced differentiation of primarily cultured bone marrow cells from the patients, colony-forming unit granulocyte-macrophage (CFU-GM) and L-CFU colony-forming assays, and karyotype analysis were performed over the treatment course. The very high bone marrow complete remission (CR) rate (94%) suggested that all-trans RA was superior to conventional chemotherapeutic regimens for the treatment of APL. 
A studied as a treatment for human acute promyelocytic leukemia (AF'L), based on in vitro documentation of induced differentiation of bone marrow cells from patients with APL.lS The results reported by several groups were very encouraging.'" In 1988, we started an all-trans RA differentiation therapy clinical trial for hospitalized patients with APL. Laboratory studies of in vitro induced differentiation of cultured bone marrow cells, L-CFU and colony-forming unit granulocyte-macrophage (CF'U-GM) colony-forming assays, and karyotype analysis were performed throughout t h e treatment course. We now report the results of the clinical trial and laboratory studies on RA-treated APL patients. D a t a o n RA therapy for maintenance of remission and for reinduction of remission are also presented and discussed.
MATERIALS AND METHODS

Clinical Data
Fifty patients with APL were hospitalized during 1988 to 1990 and diagnosed by the Clinical Hematology Division of our hospital using the criteria of the French-American-British (FAB) cooperative study group. These patients, 26 males and 24 females, had an average age of 28.9 years (range, 7 to 56 years). Forty-seven patients were previously untreated and three (nos. 16, 19, and 21) had relapsed from a previous complete remission (CR) induced by conventional chemotherapy. The patients were subdivided into 31 cases with coarse granules and 19 with fine granules based on microscopic observation of routine smears. Clinical data from these patients are shown in Table 1 . The average percentage of promyelocytes in the marrow at first presentation was 82.9% (range, 59% to 97.5%). One relapsed patient had 25.5% marrow promyelocytes. All patients had hemorrhage including purpura, subcutaneous ecchymosis, gum bleeding, epitaxis, melena, and hematuria of various degrees of severity. Twenty-four patients had severe bleeding with platelets less than 30 x 10g/L, although only nine patients had definite laboratory evidence of disseminated intravascular coagulation (DIC) (thrombin time, prothrombin time, plasma protamin sulfate paracoagulation test, and fibrinogen level). An additional six patients had equivocal laboratory evidence of DIC, and 35 patients had no evidence.
Oral all-trans retinoic acid (RA) tablets (10 mg) were kindly provided by the pharmaceutical department of Rei Jin Hospital, affiliated to the Second Shanghai Medical University.
reason for the failure of the RA treatment. Patients who relapsed after a chemotherapy-maintained CR could be effectively reinduced to second CR by RA. However, if relapse occurred after a CR maintained by both RA and chemotherapy, the sensitivity of newly emerged leukemic clones to RA was greatly reduced. Therefore, it is suggested that RA should be replaced by conventional chemotherapy as soon as CR is achieved. Laboratory studies proved valuable in selecting cases for RA therapy and in predicting therapeutic effects and prognosis. 0 1991 by The American Society of Hematology.
Laboratory Studies
Iliac-aspirated bone marrow cells were isolated by Ficoll-Hypaque centrifugation (specific gravity, 1.077). Mononuclear cells (MNC) collected from the interface were resuspended in RPMI 1640 medium complemented with 10% fetal calf serum at an initial cell density of 2 to 5 X 10S/mL. All cultured marrow cells were incubated at 37°C in a humidified atmosphere with 5% CO, for up to 5 days. Cell density was measured by hemacytometer, and cell viability was determined by trypan blue exclusion. Cell slides prepared by cytospin centrifugation were stained with Wright-Giemsa solution or histochemically stained with other standard procedures, and differential cell counts were obtained by light microscopy.
Freshly isolated marrow cells were cultured with or without 1 pmolIL of all-trans RA for 5 days. Aliquots of each cell culture were removed at different time points. Nitroblue tetrazolium (NBT) reduction assay was performed on these aliquots as described by Francis et al. ' The percentage of cells containing intracellular blue-black deposits was determined on Wright's-stained slides to assess myeloid terminal differentiation. For each fresh specimen of marrow, cell culture without RA was used for a negative control to rule out spontaneous differentiation. A long-term culture of HL-60 human promyelocytic leukemia served as a positive control.8 Whenever required, the cell culture was extended to 7 days to achieve a full induction of differentiation.
Leukemic blast cell colonies were grown as previously described' except for the conditioned medium, which was derived from the supernatant of the culture of a human bladder carcinoma cell line, HTB-9. CFU-GM assay was per-
Marrow cell culture and morphologic examination.
In vitro induced differentiation determination. Karyotypes were analyzed by R-banding technique on at least 30 metaphases for each specimen."
Forty-seven patients in first admission were administered oral all-trans RA 60 to 80 mg per day as the single therapeutic agent until CR was achieved. Peripheral blood counts, bone marrow aspiration, and coagulation parameters were determined before the commencement of RA treatment and at certain intewals thereafter. CR was defined as blasts plus promyelocytes less than 5% in a marrow with normal cellularity associated with normal peripheral blood counts. Signs and symptoms of leukemia were absent. Blood transfusion and antibiotics were administered as supportive treatment when necessary. Heparin was administered when deemed necessary. Three other patients (nos. 2, 8, and 18) were entered on the RA therapeutic trial after the failure and discontinuation of previous conventional chemotherapy.
In general, after CR was attained, patients were further treated with standard chemotherapy. Consolidation therapy consisted of homoharringtonine 2 to 3 mg intravenously (IVgtt) for 5 to 7 days; VCR 2 mg IV qw; Ara-C 50 mg intramuscularly (IM) bid for 5 to 7 days; prednisone 40 mg PO for 5 to 7 days (HOAP). Subsequently, maintenance therapy consisting of &thioguanine 50 mg PO twice daily for 4 days and Ara-C 50 mg twice daily on day 5. Methotrexate 10 mg was administered intrathecally two to three times to prevent central nervous system (CNS) leukemia. Maintenance chemotherapy continued as long as the peripheral white count was above 3 x N9/L and the patient was tolerating it well. In addition, eight patients (nos. 1,2,3,4,9,18,19, and 29) also received RA at a reduced dose (30 to 40 mgid) during postremission therapy. However, most patients (39 cases) had RA discontinued as soon as CR was attained. A bone marrow examination was performed approximately every 3 months during remission.
Higher dose RA (100 to 120 mg/d) was administered to some patients who relapsed (myeloblasts plus promyelocytes in the marrow > 20%). Other chemotherapeutic regimens were administered to patients who developed resistance to RA. Two patients (nos 29 and 35) in first CR were selected to be treated with autologous bone marrow transplantation. Postrelapse therapy is detailed in Table 2 .
Karyotype analysis.
Treatment of patients.
Maintenance therapy following CR
Further treatment for patients who relapsed.
RESULTS
Treatment Course and Clinical Effects of
RA Induction Therapy
All patients who received all-trans RA as a single agent responded to the drug. The percentage of promyelocytes in the peripheral blood began to decrease after a mean of 9.6 days (range, 5 to 12 days) of administration of RA, and all the myeloblasts and promyelocytes in the peripheral blood disappeared by a mean of 15 days (range, 10 to 24 days). Patients achieved bone marrow CR in a mean of 38.9 days (range, 25 to 70 days). The overall RA-induced bone marrow first CR rate was 94% (47 of 50). During the treatment course, the peripheral white blood cell (WBC) count exhibited a specific pattern of change characterized by a progressive increase beginning with the initiation of treatment and reaching a peak on day 12 to 14, followed by a gradual decrease to the normal range with myeloid were observed. On average, the peak platelet count occurred at approximately day 25. Blood hemoglobin concentration recovered late and sometimes fairly slowly. A representative pattern of alteration of major parameters in the peripheral blood picture after RA administration is shown in Fig 1. Clinically, most seriously ill patients had slow, steady resolution of their illness during RA treatment.
Major side effects of RA therapy included dryness of mouth and lips (46 cases), hyperkeratosis (39 cases), and cutaneous infection (8 cases), especially perineal skin infection and mild exfoliation. Hepatic and renal function were not affected by this dose of RA. These side effects were usually alleviated after the dose of RA was reduced and anti-infectious treatment was applied. Two untreated patients with severe hemorrhage on admission (a hematuria in no. 6 and a soft tissue hematoma in no. 7) finally died of intracerebral hemorrhage within 1 week, although the in vitro study on their marrow cells showed some responsiveness to RA. One case (no. 24) suddenly developed a wide subcutaneous hemorrhage with strong evidence of DIC on day 13 of RA treatment when his WBC count reached 20 x lO"/L; it was soon corrected by heparin and CR was eventually achieved.
Maintenance of CR and Treatment for Patients Who Relapsed
Up to October 1990, the average duration of RA-induced first CR in 47 patients was 14.7 months (varied from 2 to 30 months). Relapse occurred in 19 patients after 2 to 25 months of CR. Among those, eight patients were maintained with chemotherapy and reduced dosage of RA during the CR. The RA was used between intervals of chemotherapy. The other 11 cases were maintained with only chemotherapy without RA treatment. The 28 patients still in CR without relapse to date were all maintained with chemotherapy.
As soon as relapse was detected, patients were immediately treated with a higher dosage of RA or another chemotherapeutic regimen ( Table 2 ). The choice of treatment depended on the responsiveness of relapsing patient to RA. Eleven patients (nos. 1 through 5,9, 18 through 20, 28, and 29) were not able to be rescued and died of relapse after the RA induced first CR. Second CR was achieved in the other eight patients (nos. 8, 14, 16, 17, 21, 22, 26, and  46) . However, four of these eight patients died subsequently of second relapse while the other four patients (nos. 14,21,26, and 46) remained in second CR. Among the 11 cases who failed to be rescued by increased dosage of RA, eight cases (nos. 1 through 4, 9, 18, 19, and 29) were maintained with low-dose RA plus chemotherapy during Abbreviations: RA T , RA in increasing dosage (100 to 120 mg/d); COAP, homoharringtonine in HOAP was replaced by cyclophosphamide 0.4 mg IV for 3 days; DOAP, homoharringtonine in HOAP was replaced by daunomycin 40 mg IV for 3 days in each course to treat those who became resistant to homoharringtonine; HOP, cytosine arabinoside in HOAP was omitted to treat those with very low WBC count; DOCcP, cytosine arabinoside in DOAP was replaced by cyclocytidine 100 mg IM bid for 5 to 7 days to treat those who became resitant to ara-C; DAP, oncovin was omitted from DOAP; HAP, oncovin was omitted from HOAP.
the first RA-induced CR, three cases (nos. 5, 20, and 28) were not, while all eight patients who succeeded to attain second CR by the chemo-RA combined therapy were treated by only chemotherapy during the first CR. The mean duration of first CR in eight cases (nos. CR maintenance the mean duration of first CR was 14.4 months. Considering that eight (nos. 8,14,16,17,21,22,26, and 46) of these 11 patients were rescued by increased dosage of RA and attained second CR, the mean total duration of CR (first CR plus second CR) in these 11 cases was 18.32 months.
Induced Differeniation of Primarily Cultured Marrow Cells
The trypan blue exclusion ratio of all the marrow cells in primary culture over 5 days of in vitro study was higher than 80%. In 14 of 16 patients before RA treatment, leukemic cells in the marrow could be induced by 1 p,mol/L RA to display myeloid differentiation after 3 to 5 days of induction in primary culture. The proportion of cells with positive NBT reduction reached 80% to 90% by the end of the experiment, which was comparable with the level achieved by RA-induced HL-60 cells. Two cases (nos. 4 and 25) who showed poor induced differentiation in vitro still had a satisfactory clinical outcome and CR was attained. The marrow cells of another case (no. 6) who died of intracerebral hemorrhage after 5 days of admission, however, also responded to RA in vitro. For four patients (nos. 5, 9, 18, and 28) relapsing after RA-induced first CR, the cultured marrow cells of two cases (nos. 9 and 18) completely lost responsiveness to RA. The NBT reduction positive cells were only 7% and 11%, respectively, after 5 days of RA induction. Neither an increased dose of RA (up to 150 mgid) nor intensified chemotherapy reversed relapse. The marrow cells of two other patients (nos. 5 and 28) still partially retained sensitivity to RA (shown in Fig 2) . An increased dosage of RA reduced the percentage of promyelocytes in both marrow and peripheral blood and improved the overall condition of these patients for 1 to 2 months. However, the progressive increase of leukemic promyelocytes could not be controlled. Eventually, all of them failed to be rescued from relapse.
Kalyotype Analysis
Among the 16 patients who had a karyotypic analysis before RA treatment, the t( 15;17) translocation was found in 14. The percentage of t(l5;17)-positive metaphases was as high as 90% to 100% of the metaphases counted in each specimen. One case demonstrated a nonspecific chromosome aberration instead of the typical t(15;17), and the other case failed to provide satisfactory metaphases due to leukopenia. After the RA-induced CR was achieved, the t(15;17) became undetectable in 13 cases. However, the translocation was shown again when three patients relapsed after CR.
L-CFU and CFU-GM Colony-Foming Assays
In eight patients who responded to RA induction, L-CFU growth was predominant (189 ? 239 colonies/2 x lo5 MNC) before treatment. The average size of the leukemic blast colony was greater than 300 cells. The CFU-GM growth was severely suppressed (2.8 10.9 colonies/2 x lo5 MNC). There were only small clusters noted in these specimens. After CR was achieved, L-CFU colonies remarkably decreased (1.2 f 2.3 colonies/2 x lo5 MNC), while the CFU-GM growth recovered to normal levels (100 ? 120 colonies/2 X lo5 MNC).
DISCUSSION
All-trans RA has been demonstrated to be an effective agent for inducing CR in APL. Our results in the present study confirm previous reports. Furthermore, the very high CR rate obtained in our study of 50 patients treated with all-trans RA demonstrated that RA is susperior to conventional chemotherapy for APL (FAB M3) patients in many aspects. The major advantages can be summarized as 100 -r For personal use only. on August 30, 2017. by guest www.bloodjournal.org From follows: (1) RA can quickly control the disseminated intravascular coagulation that is associated with AF' L in many patients. ( 2 ) The WBC count increased rather than decreased when the leukemic promyelocytes were induced by RA to differentiate into mature granulocytes with relatively normal function. Bone marrow suppression infrequently occured. (3) Side effects were usually mild and well tolerated. (4) The cost of treatment with RA was far lower than that of standard chemotherapy. Because the treatment did not usually require hospitalization, RA therapy is more convenient for the patient.
The very high probability of the t(15;17) karyotype indicated the existence of a leukemic blast clone with the marker chromosome in the marrow of the untreated AF'L patients. However, the disappearance of t(15;17) after CR was probably not due to alteration of the genotype of the leukemic clone by RA or the elimination of the leukemic clone, but rather the diminution of the leukemic clone caused by RA-induced differentiation accompanied by the loss of proliferation capacity. The observation that the L-CFU colonies remarkably decreased and the CFU-GM colonies recovered to normal levels after RA-induced CR was consistent with this hypothesis. In addition, the t( 15;17) aberration reemerged in three patients when relapse occurred. Although the marrow leukemic cells of some relapsing patients became less sensitive or even resistant to RA, there were no substantial differences between the karyotype of those patients before RA treatment and after relapse. It is not clear in such patients if the RA resistant leukemic clone was newly developed or was derived from the previous clone, which acquired the resistance to RA by some unknown mechanism.
The clinical effects of R A treatment were theoretically based on the concept that RA overcame the blockage at promyelocytic stage to allow myeloid terminal differentiation, but RA could not prevent the occurrence of malignant transformation of myeloid progenitor cells. A combination of RA with chemotherapeutic agents was thought to be more effective in induction and maintenance of CR than RA alone, because the diminution of the leukemic clone was achieved by a complementary mechanism of chemotherapeutic killing and RA-induced differentiation. Recently, based on the observation of 50 patients in RA-induced CR with different treatment protocols, Sun et a1 claimed that the alternate administration of chemotherapy and RA was better than chemotherapy alone as maintenance treatment for patients in RA-induced CR.13 However, continuing therapy for patients in RA-induced CR is still controversial. According to our results, eight patients who were treated with RA accompanied by chemotherapy in CR all relapsed. The average duration of CR in these patients was 12.75 months, while 11 of 39 patients who were treated by chemotherapy in CR relapsed (relapsing rate, 28%). The average duration of CR in these patients was 14.4 months, and even longer (18.32 months) if the duration of second CR was included. In addition, all 28 patients presently in first CR were maintained with chemotherapy alone. The average duration of CR to date in these patients was 15.17 months, with the longest being 30 months. The survival curves of the two groups of patients are shown in Fig 3. Secondly, all eight patients became resistant to RA when they relapsed after CR maintained by chemotherapy plus RA, while only three of 11 patients became more or less resistant to RA when they relapsed after CR maintained without RA. For the other eight of these 11 cases, RA was still efficient enough to induce a second CR in them. To prolong effectiveness of RA, it is suggested that RA should be discontinued once CR is achieved. Maintenance therapy with low-dose RA after CR was of no benefit to our patients and appeared to make the drug ineffective after relapse. Furthermore, it is also suggested that RA can be used only as an initial therapy to minimize the risk of DIC. When the number of leukemic promyelocytes starts to decrease, RA can be replaced by conventional chemotherapy to complete CR. In this way, resistance to RA may also be forstalled. The mechanism of relapse after RA-induced CR and the reason for lower sensitivity of the relapsing leukemic clone to RA are two important issues to be understood before RA can be optimally used in patients with APL.
